Using Iguratimod to treat chronic graft-versus-host disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 3 clinical trial evaluates the safety and efficacy of Iguratimod, a medication typically used for rheumatoid arthritis, in patients with chronic graft-versus-host disease (cGVHD). The study is randomized and single-center, focusing on participants who have undergone allogeneic hematopoietic stem cell transplantation and have persistent cGVHD symptoms. Iguratimod is believed to have anti-inflammatory and immune-modulating effects that could alleviate symptoms similar to those seen in Sjögren's syndrome, such as dry mouth and dry eyes. The trial aims to determine if Iguratimod can improve quality of life and lung function in these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients aged ≥18 years who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), regardless of gender.
2. Those with persistent manifestations of chronic graft-versus-host disease (cGVHD) and suitable for systemic treatment.
3. Previously received at least 1 but not more than 5 lines of systemic treatment for cGVHD.
4. Corticosteroid therapy dose stable for the two weeks before screening; or, if taking prednisone or an equivalent dose of other corticosteroids at a dose \>0.5mg/kg/day for four weeks, with ongoing cGVHD manifestations and no improvement; or, if two attempts to taper steroids to a lower dose have failed, and it is necessary to increase the prednisone dose to \>0.25mg/kg/day or an equivalent dose.
5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score: 0\~1.
6. Anticipated survival of more than 12 months.

   General criteria:
7. Serum pregnancy test negative for women of childbearing age during the screening period.
8. Sexually active women of childbearing age participating in this study must agree to contraception during the trial and after the last dose of medication.

Exclusion Criteria:

1. Patients who have received experimental treatment for systemic cGVHD within the 28 days prior to enrollment, which was effective and could completely alleviate immunosuppression.
2. Blood cancer relapse (according to the corresponding criteria for relapse of the primary blood cancer) or post-transplant lymphoproliferative disease at the time of screening.

   Laboratory tests:
3. Absolute neutrophil count (ANC) \<1.5×10\^9/L (excluding GVHD as the cause).
4. Platelet count \<50×10\^9/L (excluding GVHD as the cause).
5. Alanine aminotransferase (ALT) \>3 times the upper limit of normal (ULN), aspartate aminotransferase (AST) \>3×ULN (excluding GVHD as the cause).
6. Total bilirubin (TBIL) \>1.5×ULN (excluding GVHD as the cause).
7. Creatinine clearance CrCl \<60 mL/min (Cockcroft-Gault formula).

   General criteria:
8. Pregnant or lactating women.
9. History of serious illness or other evidence indicating a serious illness, or any other condition that the investigator believes may make the subject unsuitable for this study.

   * History of severe cardiovascular disease \[New York Heart Association (NYHA) functional class III or IV\], including but not limited to ventricular arrhythmias requiring clinical intervention, uncontrolled hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg); within 6 months prior to enrollment, there is unstable angina, acute coronary syndrome, congestive heart failure, stroke, or other cardiovascular events of class III or above; at screening, NYHA functional class ≥II or left ventricular ejection fraction (LVEF) \<50% on echocardiography.
   * Unable to take oral medications, with severe (NCI CTCAE v5.0 ≥ grade 3) chronic gastrointestinal dysfunction, the presence of malabsorption syndrome, or any other condition affecting gastrointestinal absorption.
   * History of clear neurological or psychiatric disorders (including epilepsy or dementia), currently suffering from psychiatric disorders, or judged by the investigator to be non-compliant and unsuitable for participation in the study.
   * History of other severe (NCI CTCAE v5.0 ≥ grade 3) systemic diseases, deemed unsuitable for participation in the clinical trial by the investigator.
10. Other circumstances in which the investigator deems it inappropriate to participate in this study.

Where it's running

• Kailin Xu
  Xuzhou, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Kailin Xu, MD.,PD.
• Email: lihmd@163.com
• Phone: 15162166166

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Belumosudil vs. Ruxolitinib for hepatic cGVHD after HSCT

  This trial tests whether belumosudil or ruxolitinib works better for hepatic chronic GVHD after a stem cell transplant in people 12 and older.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07794514

• GT729 universal cell injection for refractory or relapsed chronic graft-versus-host disease

  This trial will try GT729 universal cell injections in adults whose chronic graft-versus-host disease has not responded to at least two prior systemic treatments after an allogeneic stem cell transplant.

  Recruiting Early Phase 1 Grit Biotechnology · Tianjin, Tianjin Municipality · NCT07253259

• BPC2001 to prevent acute graft-versus-host disease after haploidentical stem cell transplant

  This trial tests whether six weekly doses of BPC2001 given with standard care can prevent acute graft-versus-host disease in adults having haploidentical stem cell transplants.

  Recruiting at 2 sites Phase 2 BioPhoenix Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07246031

• Donor-derived regulatory T cell infusion with interleukin-2 for refractory chronic GVHD

  This will try infusing donor-derived regulatory T cells together with low-dose recombinant interleukin-2 in adults with steroid-refractory or steroid-dependent chronic graft-versus-host disease.

  Recruiting Early Phase 1 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT06920199

• Combination treatment for chronic Graft-versus-Host Disease

  This study is testing a new combination treatment with Axatilimab and light therapy to see if it helps people with chronic Graft-versus-Host Disease who haven't responded well to other treatments.

  Recruiting at 3 sites Phase 2 University of Miami · San Francisco, California and 2 other locations · NCT06663722

• Observational study for patients at risk of chronic graft-versus-host disease

  This study is tracking the health of people who have recently had a stem cell transplant to see if they develop chronic graft-versus-host disease over the next few months.

  Recruiting at 36 sites Incyte Corporation · Birmingham, Alabama and 36 other locations · NCT05919511

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.